SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 3644.
  • 2
    Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982; 128: 24537.
  • 3
    Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti–B cell therapy [review]. Arthritis Rheum 2003; 48: 148492.
  • 4
    Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al, for the International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum 2001; 44: 91220.
  • 5
    Russell KA, Wiegert E, Schroeder DR, Homburger HA, Specks U. Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol 2002; 103: 196203.
  • 6
    Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44: 283640.
  • 7
    Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 48898.
  • 8
    Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 102132.
  • 9
    Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999; 103: 88594.
  • 10
    Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43: 202533.
  • 11
    Heeringa P, Tervaert JW. Pathophysiology of ANCA-associated vasculitides: are ANCA really pathogenic? Kidney Int 2004; 65: 15647.
  • 12
    Leyendeckers H, Tasanen K, Bruckner-Tuderman L, Zillikens D, Sitaru C, Schmitz J, et al. Memory B cells specific for the NC16A domain of the 180 kDa bullous pemphigoid autoantigen can be detected in peripheral blood of bullous pemphigoid patients and induced in vitro to synthesize autoantibodies. J Invest Dermatol 2003; 120: 3728.
  • 13
    Goodnow CC. Pathways for self-tolerance and the treatment of autoimmune diseases. Lancet 2001; 357: 211521.
  • 14
    Eriksson P. Short-term outcome and safety in 5 patients with ANCA-positive vasculitis treated with rituximab [abstract]. Kidney Blood Press Res 2003; 26: 294.
  • 15
    Jayne DR, Burns S, Smith K. B-cell depletion with rituximab for refractory vasculitis [abstract]. Kidney Blood Press Res 2003; 26: 294.